hotspot -WSS

hotspot

author：entertainment 2025-09-29 19:57:57 - browse：98926

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Living with Fabry disease, a condition that causes chronic pain

focus

WSS

PBM executives asked to testify by House panel

Most antidepressants don't work on kids, teens, study finds

Brain technologies pose threats that are all too real, experts warn

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

Welsh Carson private equity firm escapes from FTC antitrust case

The creative science of coining drug names

focus

hotspot

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Petition to FDA: Get the lead out of consumer hair dyes

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

N.Y. state detects polio case, first in the U.S. since 2013

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Palantir health business leans on meeting customers’ needs

Wildfire smoke exposes gaps in outdoor worker protections

PBM executives asked to testify by House panel

DIEP, the 'gold standard' of breast reconstruction, is under threat

How the political right came to back psychedelics to treat trauma

leisure time

Primary care doctor shortage won't be solved by free med school tuition

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

BIO to announce reorganization, senior leaders expected to depart

Study: Pain burden is higher in Black NFL players than white ones

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

Why ADHD is under

hotspot

entertainment

focus

focus